The FDA has approved Lexapro (escitalopram oxalate, from Forest Laboratories) for the acute and maintenance treatment of major depressive disorder (MDD) in adolescents 12–17 years of age. This approval was based on results from two 8-week flexible-dose, placebo-controlled studies. In both studies, Lexapro showed statistically significantly greater mean improvement from baseline, compared to placebo, on the Children’s Depression Rating Scale-Revised (CDRS-R).
Lexapro is already indicated in adults for the acute and maintenance treatment of MDD and for the acute treatment of generalized anxiety disorder (GAD).
For more information call (800) 678-1605 or visit www.lexapro.com.